Tipifarnib in hematologic malignancies

I. Rationale for using Tipifarnib in hematologic malignancies Signal transduction pathways regulate the cell processes of growth differentiation and survival. Aberrations in signal transduction pathways can lead to increased cell proliferation, apoptosis inhibition, increased angiogenesis, tissue invasion and metastasis. Most human neoplasias have aberrant signal transduction elements. Therefore signal transduction inhibitors represent a new class of compounds potentially active in cancer treatment. These agents target proteins or pathways that are involved in the pathogenesis of malignancies.